65.83 0.00 (0.00%)
After hours: 4:15PM EDT
|Bid||65.66 x 800|
|Ask||67.99 x 1000|
|Day's range||63.97 - 66.37|
|52-week range||26.56 - 78.75|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2020 - 14 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.00|
(Bloomberg) -- Khloe Kardashian is adding another role to her already busy schedule, migraine ambassador.The social influencer, who has been criticized for past associations with weight loss teas and smoothies has joined forces with Biohaven Pharmaceutical Holding Co. to promote its migraine medicine, Nurtec ODT. Sales of the tablet in the first quarter were $1.2 million after the drug was approved in February.Nurtec ODT is seen generating about $50 million in revenue this year and topping $1 billion by 2024, according to the average of analysts’ estimates. Time will tell if its association with a Kardashian will spur the migraine medicine into what the industry calls blockbuster status sooner.More women suffer from migraines than men, and a smattering of new drugs has offered hope for the often disabling condition. Biohaven faces stiff competition from large-cap drugmakers like Amgen Inc. and the Danish drug company H. Lundbeck A/S. Shares in New Haven Connecticut-based Biohaven rose as much as 3.6% on Wednesday after the announcement.(Updates shares in fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
NEW HAVEN, Conn., July 08, 2020 -- Kleo Pharmaceuticals, a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate.
NEW HAVEN, Conn., June 01, 2020 -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to.
A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.
NEW HAVEN, Conn., May 21, 2020 -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to.
Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced preclinical data for the company’s lead program, KP1237 in combination with autologous, cytokine-induced, memory-like (CIML) natural killer (NK) cells with low dose IL-2 in multiple myeloma (MM). This research, in collaboration with Dr. Rizwan Romee, Director of the Haploidentical Donor Transplantation Program at the Dana Farber Cancer Institute, will be presented as a poster and highlight the activity of the combination of KP1237 with CIML NK cells against CD38-expressing MM target cells.
Anyone researching Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) might want to consider the historical...
Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...